PRESS RELEASE published on 11/19/2025 at 00:00, 2 months 15 days ago Onco-Innovations Advances AI and Quantum Drug Discovery with Kuano Collaboration to Accelerate PNKP Inhibitor Technology Development Onco-Innovations partners with Kuano Ltd. to accelerate development of PNKP Inhibitor Technology, leveraging quantum analytics for cancer therapeutics. Details on advanced collaboration Cancer Therapeutics Onco-Innovations Quantum Analytics Kuano Ltd. PNKP Inhibitor Technology
BRIEF published on 11/08/2025 at 00:05, 2 months 26 days ago Onco-Innovations' Inka Health Enhances Global Medical Data Use Health Technology Oncology Real-world Evidence Rare Diseases Data Transportability
BRIEF published on 11/08/2025 at 00:05, 2 months 26 days ago Inka Health d'Onco-Innovations améliore l'utilisation des données médicales à l'échelle mondiale Oncologie Maladies Rares Technologies De La Santé Preuves Issues Du Monde Réel Portabilité Des Données
PRESS RELEASE published on 11/08/2025 at 00:00, 2 months 26 days ago Onco-Innovations' Inka Health Publishes Framework on Transportability of Real-World Evidence and Use in Health Technology Assessment Onco-Innovations Limited's subsidiary, Inka Health Corp., publishes primer on transportability of real-world evidence in oncology, outlining key statistical methods and potential impact on rare disease drug approvals Oncology Real-world Evidence Rare Diseases Onco-Innovations Limited Inka Health Corp.
BRIEF published on 10/31/2025 at 23:05, 3 months 3 days ago Onco-Innovations poursuit une croissance stratégique aux États-Unis suite à l'intérêt des investisseurs. Essais Cliniques Relations Avec Les Investisseurs Traitement Du Cancer Onco-Innovations Stratégie Américaine
BRIEF published on 10/31/2025 at 23:05, 3 months 3 days ago Onco-Innovations Pursues Strategic U.S. Growth Following Investor Spotlight Investor Relations Clinical Trials Cancer Treatment Onco-Innovations U.S. Strategy
PRESS RELEASE published on 10/31/2025 at 23:00, 3 months 3 days ago Onco-Innovations Provides Shareholder Update Following Cboe Canada Investor Spotlight Onco-Innovations Limited updates strategic objectives focusing on U.S. strategy, including plans for clinical trials, U.S. stock exchange listing, and growth initiatives Clinical Trials Stock Exchange Listing Growth Initiatives Onco-Innovations Limited U.S. Strategy
BRIEF published on 10/31/2025 at 02:05, 3 months 4 days ago Onco-Innovations Welcomes Jared Rushton to Its Board Capital Markets Online Marketing Board Appointment Biotech Sector Corporate Development
BRIEF published on 10/31/2025 at 02:05, 3 months 4 days ago Onco-Innovations accueille Jared Rushton au sein de son conseil d'administration Marketing En Ligne Nomination Au Conseil D'administration Marchés Des Capitaux Secteur De La Biotechnologie Développement D'entreprise
PRESS RELEASE published on 10/31/2025 at 02:00, 3 months 4 days ago Onco-Innovations Appoints Jared Rushton to Board of Directors Onco-Innovations Limited appoints Jared Rushton to Board of Directors & engages MCS Market Communication Service GmbH for online marketing services. Company focuses on cancer research & treatment Cancer Research Onco-Innovations Limited MCS Market Communication Service GmbH Online Marketing Services Jared Rushton
Published on 02/04/2026 at 02:15, 10 hours 35 minutes ago Future Fuels Announces $2 Million LIFE Flow-Through Offering
Published on 02/04/2026 at 00:00, 12 hours 50 minutes ago Sintana Energy Inc. Announces VMM-37 Resolution
Published on 02/03/2026 at 23:30, 13 hours 20 minutes ago FutureGen Industries Retains Market-Making Services
Published on 02/03/2026 at 23:12, 13 hours 38 minutes ago Appointment of Credit Advisor for Stage 1 Operations
Published on 02/03/2026 at 22:30, 14 hours 20 minutes ago Green Bridge Announces Closing of Non-Brokered Private Placement for Gross Proceeds of C$4 Million
Published on 02/04/2026 at 12:30, 20 minutes ago Alibaba Brings Cloud-Based AI Innovation to Milano Cortina 2026 Winter Olympics
Published on 02/04/2026 at 12:30, 20 minutes ago Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
Published on 02/04/2026 at 11:55, 55 minutes ago Form 8.3 - Lupus alpha Asset Management AG: Kitwave Group plc
Published on 02/04/2026 at 11:43, 1 hour 6 minutes ago Schweizer Electronic AG significantly strengthens its ESG profile with a CDP climate rating of ‘B’
Published on 02/04/2026 at 11:59, 50 minutes ago LNA Santé : Répartition de capital et des droits de vote attachés aux actions au 31/01/2026
Published on 02/04/2026 at 11:51, 58 minutes ago Janvier 2026 - Déclaration sur le nombre d'actions composant le capital social et sur le nombre de droits de vote correspondant
Published on 02/03/2026 at 18:00, 18 hours 50 minutes ago Mint dépasse ses ambitions annoncées pour 2025 grâce à des succès commerciaux majeurs dans le BtoB
Published on 02/03/2026 at 17:45, 19 hours 5 minutes ago Informations relatives au nombre total de droits de vote et d’actions